重新检查用于胸膜瘤的新辅助疗法:一条漫长而曲折的道路
Fenghao Yu1, Zhitao Gu1, Xuefei Zhang1
1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Cancers
|May 11, 2024
概括
术前治疗可以改善晚期胸膜上皮瘤 (TETs) 的手术结果. 对新辅助化疗,化疗和新疗法 (如TETs免疫疗法) 的证据进行了审查,以指导临床实践.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 医学研究 医学研究
背景情况:
- 晚期胸膜上皮瘤 (TETs) 的完全切除显著改善了预后.
- 术前治疗有时是必要的,以实现完全的瘤切除当初级手术是不够的.
- 新辅助化疗的疗效在胸腺瘤中得到了很好的研究,但在胸腺癌中理解程度较低.
研究的目的:
- 审查目前关于高级胸膜上皮瘤 (TETs) 手术前疗法的证据.
- 评估新辅助化疗,化疗和新疗法在术前环境中的作用.
- 为当前的临床实践和TET管理的未来研究方向提供见解.
主要方法:
- 关于胸膜上皮瘤手术前疗法研究的文献综述.
- 对新辅助化疗,化疗,免疫疗法和向疗法的数据分析.
- 综合各种手术前治疗方式的疗效和局限性的证据.
主要成果:
- 新辅助化疗是最常见的手术前疗法,在胸腺瘤中已确立有效性,但在胸腺癌中数据有限.
- 新辅助化学辐射已经在有限的研究中得到了探索.
- 免疫疗法和向疗法在复发/转移性TET中表现有前途,但它们在手术前的作用仍在研究中.
结论:
- 术前治疗对于优化晚期TET手术切除至关重要.
- 需要进一步的研究来澄清不同新辅助方法的疗效,特别是在胸腺癌中.
- 新型疗法需要研究,作为TETs的潜在手术前治疗选择.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.